What is the role of thrombopoietin receptor agonists (TPO-RA) in the treatment of myelodysplastic syndrome (MDS)?

Updated: Jul 24, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print

Thrombopoietin receptor agonists (TPO-RA) such as romiplostim and eltrombopag have been approved to treat immune thrombocytopenia. Their use in MDS is limited in current practice owing to the increase in the blast percentage seen with the use of eltrombopag in some studies.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!